mhurhangee/ep-ind-claims huggingface dataset:
A liquid phase diffusion bonded pipe coupling comprising a metal coupling and a metal pipe, the metal coupling provided with a tapered slanted part tightly engaging with said end and a joining surface part continuing from said tapered slanted part and joined with an end face of the metal pipe by liquid phase diffusion bonding characterised in that: the tapered slanted part of the metal coupling is press-fit into the end of the metal pipe by a pushing force in a pipe axial direction while enlarging said metal pipe in inside diameter, and further characterised in that a thickness of the end of the metal pipe tightly engaged with said tapered slanted part in said enlarged state is larger than the average value of the thickness of the thickness of the not expanded part of the body of the metal pipe, wherein the increase of the thickness of this end of the metal pipe is due to imparting a thrust in the heated state of the liquid phase diffusion bonding. the tapered slanted part of the metal coupling is press-fit into the end of the metal pipe by a pushing force in a pipe axial direction while enlarging said metal pipe in inside diameter, and further characterised in that a thickness of the end of the metal pipe tightly engaged with said tapered slanted part in said enlarged state is larger than the average value of the thickness of the thickness of the not expanded part of the body of the metal pipe, wherein the increase of the thickness of this end of the metal pipe is due to imparting a thrust in the heated state of the liquid phase diffusion bonding.
Horizontal tail plane for an aircraft comprising: - A leading edge, - A trailing edge, - Upper and lower skins including a part of the aerodynamic profiles of the leading edge and the trailing edge, - A mid-box that forms the structural support for upper and lower skins comprising a front spar and a rear spar, - Leading edge ribs attached to the front spar of the mid-box and to the aerodynamic profile of the leading edge, and - a one piece main rib attached to the front spar and to the rear spar of the mid-box, the main rib having a length that exceeds the distance between front spar and rear spar, characterized in that the main rib is formed by an H-shaped profile and comprises intermediate flanges to secure the rear spar. - A leading edge, - A trailing edge, - Upper and lower skins including a part of the aerodynamic profiles of the leading edge and the trailing edge, - A mid-box that forms the structural support for upper and lower skins comprising a front spar and a rear spar, - Leading edge ribs attached to the front spar of the mid-box and to the aerodynamic profile of the leading edge, and - a one piece main rib attached to the front spar and to the rear spar of the mid-box, the main rib having a length that exceeds the distance between front spar and rear spar,
An inhaler for metered dose inhalation, the inhaler comprising a main body having a canister housing arranged to retain a medicament canister for motion therein, and a dose counter, the dose counter having an actuation pin having at least a portion thereof located in the canister housing for operation by movement of a medicament canister, wherein the canister housing has an inner wall, and wherein the inhaler further comprises a first inner wall canister support formation, characterised in that the canister support formation is located directly adjacent the actuation pin.
A power line communication system, comprising: multiple slaves; multiple masters connected to the multiple slaves via one or more power lines; a detector (28; 34); and a processor (29; 35), each of the multiple masters including a storage circuit configured to store a set of identification information of slaves which are of the multiple slaves and are allowed to communicate with a master including this storage circuit, being configured to communicate, via the one or more power lines, with one or more slaves identified by identification information contained in the set stored in the storage circuit thereof, the detector (28; 34) being configured to, when at least two sets of the sets stored in the storage circuits of the multiple masters contain same identification information in common, determine occurrence of duplication of identification information, and the processor (29; 35) being configured to, when the detector (28; 34) determines the occurrence of the duplication, perform a process of associating each of the multiple slaves with any one of the multiple masters to eliminate the duplication, characterized in that the processor (29; 35) is configured to, in a case where the detector (28; 34) determines the occurrence of the duplication, when at least one of at least three sets of the sets stored in the storage circuits of the multiple masters is a subset of a union of remaining sets of the at least three sets, give an announcement that a master corresponding to the subset is omittable. multiple slaves; multiple masters connected to the multiple slaves via one or more power lines; a detector (28; 34); and a processor (29; 35), each of the multiple masters including a storage circuit configured to store a set of identification information of slaves which are of the multiple slaves and are allowed to communicate with a master including this storage circuit, being configured to communicate, via the one or more power lines, with one or more slaves identified by identification information contained in the set stored in the storage circuit thereof, the detector (28; 34) being configured to, when at least two sets of the sets stored in the storage circuits of the multiple masters contain same identification information in common, determine occurrence of duplication of identification information, and the processor (29; 35) being configured to, when the detector (28; 34) determines the occurrence of the duplication, perform a process of associating each of the multiple slaves with any one of the multiple masters to eliminate the duplication, characterized in that the processor (29; 35) is configured to, in a case where the detector (28; 34) determines the occurrence of the duplication, when at least one of at least three sets of the sets stored in the storage circuits of the multiple masters is a subset of a union of remaining sets of the at least three sets, give an announcement that a master corresponding to the subset is omittable.
A dosage form comprising: a) a core having a center portion, a first end and a second end; and b) a coating over the center portion of the core; wherein said coating is comprised of: 1) gelatin; or 2) a polymer, a starch, a hydrocolloid, or combinations thereof; wherein said polymer comprises hypromellose, hydroxypropylcellulose methylcellulose, pullulan, polyvinylalcohol, polymethacrylate, or mixtures, co-polymers and combinations thereof; wherein said starch comprises modified starches or cornstarch; wherein said hydrocolloid comprises gellan gum, xanthan gum, guar gum, carageenan, or mixtures thereof; wherein a portion of the first end of the core and a portion of the second end of the core are exposed; and wherein said core comprises at least one active ingredient, and wherein at least 40%, preferably at least 60%, of said at least one active ingredient dissolves within 3 minutes in 900 mLs of water when tested using USP dissolution apparatus II with a paddle speed of 50 rpm. a) a core having a center portion, a first end and a second end; and b) a coating over the center portion of the core; wherein said coating is comprised of: 1) gelatin; or 2) a polymer, a starch, a hydrocolloid, or combinations thereof; wherein said polymer comprises hypromellose, hydroxypropylcellulose methylcellulose, pullulan, polyvinylalcohol, polymethacrylate, or mixtures, co-polymers and combinations thereof; wherein said starch comprises modified starches or cornstarch; wherein said hydrocolloid comprises gellan gum, xanthan gum, guar gum, carageenan, or mixtures thereof; wherein a portion of the first end of the core and a portion of the second end of the core are exposed; and wherein said core comprises at least one active ingredient, and wherein at least 40%, preferably at least 60%, of said at least one active ingredient dissolves within 3 minutes in 900 mLs of water when tested using USP dissolution apparatus II with a paddle speed of 50 rpm. 1) gelatin; or 2) a polymer, a starch, a hydrocolloid, or combinations thereof; wherein said polymer comprises hypromellose, hydroxypropylcellulose methylcellulose, pullulan, polyvinylalcohol, polymethacrylate, or mixtures, co-polymers and combinations thereof; wherein said starch comprises modified starches or cornstarch; wherein said hydrocolloid comprises gellan gum, xanthan gum, guar gum, carageenan, or mixtures thereof; wherein a portion of the first end of the core and a portion of the second end of the core are exposed; and wherein said core comprises at least one active ingredient, and wherein at least 40%, preferably at least 60%, of said at least one active ingredient dissolves within 3 minutes in 900 mLs of water when tested using USP dissolution apparatus II with a paddle speed of 50 rpm.
A curable composition comprising: (a) at least one fluorinated polymer; (b) at least one curing agent of formula; and (c) at least one fluorinated aromatic compound; wherein in formula each R, equal to or different from each other, is independently selected from the group consisting of hydrogen; halogen; C 1 -C 20 alkyl, linear or branched, optionally substituted and/or optionally fluorinated; C 1 -C 20 oxyalkyl, linear or branched, optionally substituted and/or optionally fluorinated; (per)fluoropolyether chain; aromatic or heteroaromatic radical, monocyclic or polycyclic, optionally substituted and/or optionally fluorinated; -SiR 1 3, -(R 1 2 SiO) b R 1, -PR 1 2 wherein each R 1, equal to or different from each other, is independently selected from the group consisting of hydrogen, C 1 -C 20 alkyl, linear or branched, optionally substituted and/or optionally fluorinated and wherein b is an integer of at least 1; and wherein A 1 and A 2, equal to or different from each other, are each independently selected from the group consisting of hydrogen; halogen; C 1 -C 20 alkyl, linear or branched, optionally substituted and/or optionally fluorinated; C 1 -C 20 oxyalkyl, linear or branched, optionally substituted and/or optionally fluorinated; (per)fluoropolyether chain; -(R 1 2 SiO) b R 1 wherein R 1 and b are as defined; aromatic or heteroaromatic radical, monocyclic or polycyclic, optionally substituted and/or optionally fluorinated; and wherein A 1 and A 2 may be comprised in an alkyl or aromatic cyclic structure, optionally substituted and/or optionally fluorinated. (a) at least one fluorinated polymer; (b) at least one curing agent of formula; and (c) at least one fluorinated aromatic compound; wherein in formula each R, equal to or different from each other, is independently selected from the group consisting of hydrogen; halogen; C 1 -C 20 alkyl, linear or branched, optionally substituted and/or optionally fluorinated; C 1 -C 20 oxyalkyl, linear or branched, optionally substituted and/or optionally fluorinated; (per)fluoropolyether chain; aromatic or heteroaromatic radical, monocyclic or polycyclic, optionally substituted and/or optionally fluorinated; -SiR 1 3, -(R 1 2 SiO) b R 1, -PR 1 2 wherein each R 1, equal to or different from each other, is independently selected from the group consisting of hydrogen, C 1 -C 20 alkyl, linear or branched, optionally substituted and/or optionally fluorinated and wherein b is an integer of at least 1; and wherein A 1 and A 2, equal to or different from each other, are each independently selected from the group consisting of hydrogen; halogen; C 1 -C 20 alkyl, linear or branched, optionally substituted and/or optionally fluorinated; C 1 -C 20 oxyalkyl, linear or branched, optionally substituted and/or optionally fluorinated; (per)fluoropolyether chain; -(R 1 2 SiO) b R 1 wherein R 1 and b are as defined; aromatic or heteroaromatic radical, monocyclic or polycyclic, optionally substituted and/or optionally fluorinated; and wherein A 1 and A 2 may be comprised in an alkyl or aromatic cyclic structure, optionally substituted and/or optionally fluorinated.
A combination of a peroxisome proliferator-activated receptor (PPAR) δ receptor selective agonist and an IGF receptor agonist for use in treating mild cognitive impairment in a human subject at risk of developing Alzheimer's Disease, wherein mild cognitive impairment is a condition related to mild signs of Alzheimer's disease pathology corresponding to Braak stages 1 to 3, and wherein the human subject to be treated is identified according to the steps of: (a) determining the level or function of at least one factor in said subject, wherein a decrease in the level or function of one or more of said factors relative to the level or function in healthy subjects is a diagnostic indicator of a risk for developing Alzheimer's Disease, thereby identifying the subject to be at risk of developing Alzheimer's Disease, and (b) administering to said subject a therapeutically effective amount of a PPAR δ receptor selective agonist in combination with a therapeutically effective amount of an IGF receptor agonist, wherein said at least one factor is selected from the group consisting of insulin, IGF-I, IGF-II, insulin receptor, IGF-I receptor, IGF-II receptor, tyrosine phosphorylated insulin receptor, tyrosine phosphorylated IGF-I receptor, tyrosine phosphorylated IGF-II receptor, insulin receptor substrate-1 (IRS-1), IRS-2, IRS-4, tyrosine phosphorylated IRS-1, tyrosine phosphorylated IRS-2, tyrosine phosphorylated IRS-4, phosphotidylinositol 3-kinase (PI3 kinase), the p85 subunit of PI3 kinase, Akt, phospho-Akt glycogen synthase kinase-3β (GSK-3β), and phospho-GSK-3β. (a) determining the level or function of at least one factor in said subject, wherein a decrease in the level or function of one or more of said factors relative to the level or function in healthy subjects is a diagnostic indicator of a risk for developing Alzheimer's Disease, thereby identifying the subject to be at risk of developing Alzheimer's Disease, and (b) administering to said subject a therapeutically effective amount of a PPAR δ receptor selective agonist in combination with a therapeutically effective amount of an IGF receptor agonist,
A common mode choke coil comprising: a magnetic core having a winding core portion and a pair of flanges (21, 22) provided at respective ends of the winding core portion; external electrodes (3-1 to 3-4) provided on the respective flanges; a pair of windings (4-1, 4-2) wound around the winding core portion, each end of the pair of the windings being extended and connected to the external electrodes; and a magnetic plate adhered to the pair of the flanges; wherein a metal film is arranged at least on a contact portion of the magnetic plate contacting the flanges (21, 22), and is formed so that when the choke coil is used the magnetic lines of force pass through the metal film. a magnetic core having a winding core portion and a pair of flanges (21, 22) provided at respective ends of the winding core portion; external electrodes (3-1 to 3-4) provided on the respective flanges; a pair of windings (4-1, 4-2) wound around the winding core portion, each end of the pair of the windings being extended and connected to the external electrodes; and a magnetic plate adhered to the pair of the flanges; wherein a metal film is arranged at least on a contact portion of the magnetic plate contacting the flanges (21, 22), and is formed so that when the choke coil is used the magnetic lines of force pass through the metal film.
A damping or return device for sliding door leaves, particularly for furniture or for drawers, comprising: - a first trolley, which is mountable on said door leaf and is slideable with respect to said item of furniture, - a diametrically differently-polarized magnet comprising mutually coupled identical polygonal first and second half-magnets (20a,20b) having opposing polarities, associated with said first trolley or mountable on said item of furniture, - at least one steel plate (21a, 21b), mountable on said item of furniture or associated with said first trolley, said first trolley interacting selectively with at least one elastically compressible element (24a, 24b) which abuts, in opening and in closing, with an abutment element (23, 27) which is associated with and protrudes from said item of furniture. - a first trolley, which is mountable on said door leaf and is slideable with respect to said item of furniture, - a diametrically differently-polarized magnet comprising mutually coupled identical polygonal first and second half-magnets (20a,20b) having opposing polarities, associated with said first trolley or mountable on said item of furniture, - at least one steel plate (21a, 21b), mountable on said item of furniture or associated with said first trolley,
A composition comprising a porous silicon substrate and an antibody bound in the pores of the substrate for use in the treatment of a wound, wherein the antibody is released from the substrate thereby administering the antibody to the wound, wherein the antibody comprises a monoclonal antibody to Flightless I or a monoclonal antibody to TNF-α.
A medical apparatus (100, 400, 600) comprising: - a memory for storing machine executable instructions; - a processor for controlling the medical apparatus, wherein execution of the machine executable instructions causes the processor to: - receive a medical image descriptive of a three-dimensional anatomy of a subject; and - provide an image segmentation by segmenting the medical image into multiple tissue regions (300, 302) using a model-based segmentation, wherein the model-based segmentation assigns a tissue type to each of the multiple regions, wherein the model-based segmentation has a surface mesh, wherein the model-based segmentation comprises a cortical bone model, and wherein the segmentation is corrected by using the tissue type assigned to each of the multiple regions to correct for partial volume effects at boundaries formed by the surface mesh between at least some of the multiple tissue regions; and - reconstruct a pseudo radiographic image using the corrected image segmentation and the tissue type assigned to each of the multiple regions, wherein execution of the machine executable instructions causes the processor to correct the pseudo radiographic image using the cortical bone model by forward simulating the partial volume effect of the corrected image segmentation in the pseudo radiographic image. - a memory for storing machine executable instructions; - a processor for controlling the medical apparatus, wherein execution of the machine executable instructions causes the processor to: - receive a medical image descriptive of a three-dimensional anatomy of a subject; and - provide an image segmentation by segmenting the medical image into multiple tissue regions (300, 302) using a model-based segmentation, wherein the model-based segmentation assigns a tissue type to each of the multiple regions, wherein the model-based segmentation has a surface mesh, wherein the model-based segmentation comprises a cortical bone model, and wherein the segmentation is corrected by using the tissue type assigned to each of the multiple regions to correct for partial volume effects at boundaries formed by the surface mesh between at least some of the multiple tissue regions; and - reconstruct a pseudo radiographic image using the corrected image segmentation and the tissue type assigned to each of the multiple regions, wherein execution of the machine executable instructions causes the processor to correct the pseudo radiographic image using the cortical bone model by forward simulating the partial volume effect of the corrected image segmentation in the pseudo radiographic image.
An actuator assembly comprising: a static part; a movable part; a helical bearing arrangement supporting the movable part on the static part and arranged to guide helical movement of the movable part with respect to the static part around a helical axis; and one or more actuators, that are not shape memory alloy actuators, arranged to drive movement of the movable part with respect to the static part around the helical axis, characterized in that the helical bearing arrangement comprises plural helical bearings that are each a rolling bearing comprising bearing surfaces (31, 32) on the static part and the movable part and at least one rolling bearing element disposed between the bearing surfaces, wherein the plural helical bearings are arranged to guide the helical movement of the movable part with respect to the static part around the helical axis. a static part; a movable part; a helical bearing arrangement supporting the movable part on the static part and arranged to guide helical movement of the movable part with respect to the static part around a helical axis; and one or more actuators, that are not shape memory alloy actuators, arranged to drive movement of the movable part with respect to the static part around the helical axis, characterized in that the helical bearing arrangement comprises plural helical bearings that are each a rolling bearing comprising bearing surfaces (31, 32) on the static part and the movable part and at least one rolling bearing element disposed between the bearing surfaces, wherein the plural helical bearings are arranged to guide the helical movement of the movable part with respect to the static part around the helical axis.
A medical device comprising: a first implantable electrode; a second implantable electrode; a current source configured to source electrical stimulation via the first implantable electrode; a current sink configured to sink the electrical stimulation via the second implantable electrode; characterised by a capacitor configured to receive, via at least one of the current source or current sink, current generated by a first voltage across the first implantable electrode and the second implantable electrode, the first voltage from an external source, and store a second voltage with the received current; and by an overvoltage protection element configured to shunt current from at least one of the first implantable electrode and second implantable electrode if the second voltage stored by the capacitor exceeds a threshold voltage of the overvoltage protection element. a first implantable electrode; a second implantable electrode; a current source configured to source electrical stimulation via the first implantable electrode; a current sink configured to sink the electrical stimulation via the second implantable electrode; characterised by a capacitor configured to receive, via at least one of the current source or current sink, current generated by a first voltage across the first implantable electrode and the second implantable electrode, the first voltage from an external source, and store a second voltage with the received current; and by an overvoltage protection element configured to shunt current from at least one of the first implantable electrode and second implantable electrode if the second voltage stored by the capacitor exceeds a threshold voltage of the overvoltage protection element.